Fiscal 2022 Budget Reconciliation Bill -- Drug Price Negotiation Exemptions

Marshall, R-Kan., amendment no. 5389 to the Schumer, D-N.Y., substitute amendment no. 5194 to the fiscal 2022 budget reconciliation bill that would exclude breakthrough therapies and certain Part D protected class drugs from Medicare price negotiations and reduce by $60.3 billion funding provided by the bill for IRS enforcement activities and operations.